Published in Mov Disord on March 01, 2006
CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron (2013) 2.94
Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A (2008) 2.91
A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry (2009) 1.98
Advances in understanding the molecular basis of FXTAS. Hum Mol Genet (2010) 1.83
FMR1: a gene with three faces. Biochim Biophys Acta (2009) 1.77
Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging (2008) 1.57
Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav (2012) 1.44
Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol (2013) 1.41
Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol (2011) 1.39
Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology (2008) 1.31
The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. J Clin Exp Neuropsychol (2008) 1.29
Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med (2009) 1.27
Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. Future Neurol (2009) 1.17
Mouse models of fragile X-associated tremor ataxia. J Investig Med (2009) 1.15
Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord (2008) 1.15
Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment. Tremor Other Hyperkinet Mov (N Y) (2012) 0.86
TDP-43 suppresses CGG repeat-induced neurotoxicity through interactions with HnRNP A2/B1. Hum Mol Genet (2014) 0.83
A Quantitative Assessment of Tremor and Ataxia in Female FMR1 Premutation Carriers Using CATSYS. Curr Gerontol Geriatr Res (2011) 0.82
Essential tremor with ubiquitinated Purkinje cell intranuclear inclusions. Acta Neuropathol (2010) 0.80
Fragile X syndrome: an aging perspective. Dev Disabil Res Rev (2013) 0.79
Fragile X mental retardation protein expression in Alzheimer's disease. Front Genet (2014) 0.78
Immune mediated disorders in women with a fragile X expansion and FXTAS. Am J Med Genet A (2014) 0.76
New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype. Front Genet (2014) 0.76
Endocrine Dysfunction in Female FMR1 Premutation Carriers: Characteristics and Association with Ill Health. Genes (Basel) (2016) 0.75
Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases. J Neurol Neurosurg Psychiatry (2014) 0.75
Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome. Ann Neurol (2016) 0.75
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Reduced Purkinje cell number in essential tremor: a postmortem study. Arch Neurol (2008) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Recognition and specificity determinants of the human cbx chromodomains. J Biol Chem (2010) 1.76
Axis is a feature of handwritten spirals in essential tremor. Mov Disord (2006) 1.70
The emerging neuropathology of essential tremor. Mov Disord (2008) 1.62
ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer (2008) 1.56
Early neuropsychological discriminants for Lewy body disease: an autopsy series. J Neurol Neurosurg Psychiatry (2013) 1.53
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Essential tremor associated with pathologic changes in the cerebellum. Arch Neurol (2006) 1.29
Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol (2005) 1.20
Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci (2011) 1.13
Fragile X syndrome detection in newborns-pilot study. Genet Med (2008) 1.12
Living at risk: concealing risk and preserving hope in Huntington disease. J Genet Couns (2007) 1.02
Novel FGFR2 deletion in a patient with Beare-Stevenson-like syndrome. Am J Med Genet A (2009) 0.88
Expansion of the ARX spectrum. Clin Neurol Neurosurg (2008) 0.84
Update on Hippocampal Sclerosis. Curr Neurol Neurosci Rep (2015) 0.81
Bioelectronic sensor technology for detection of cystic fibrosis and hereditary hemochromatosis mutations. Arch Pathol Lab Med (2003) 0.81
Evaluation of land use regression models for NO2 in El Paso, Texas, USA. Sci Total Environ (2012) 0.80
X-linked creatine transporter deficiency presenting as a mitochondrial disorder. J Child Neurol (2010) 0.79
Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model. J Neuropathol Exp Neurol (2015) 0.79
Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. Acta Neuropathol Commun (2014) 0.79
Presenting neuropsychological testing profile of autopsy-confirmed frontotemporal lobar degeneration. Dement Geriatr Cogn Disord (2013) 0.78
Survey of community-based programs serving U.S. families with Huntington's disease: perceived barriers and facilitators in the residential placement process. Care Manag J (2008) 0.78
Dementia with cerebrovascular disease. Sci Aging Knowledge Environ (2006) 0.77
Generation of iPSC lines from archived non-cryoprotected biobanked dura mater. Acta Neuropathol Commun (2014) 0.77
Huntington's disease: a caring approach to the end of life. Care Manag J (2008) 0.77
Late-life action tremor in a southern sea otter (enhydris lutris nereis). Mov Disord (2004) 0.76
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol (2016) 0.76
Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease. Mol Brain (2013) 0.76
What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns (2010) 0.75
Electronic tracking of human brain samples for research. Cell Tissue Bank (2008) 0.75
Reflections: neurology and the humanities. Odd harvest. Neurology (2014) 0.75
Feasibility and validity of a modified finger-nose-finger test. Mov Disord (2005) 0.75